ISSN: 1747-4086

Journal Home

Journal Guideline

Expert Review of Hematology Q2 Unclaimed

Taylor and Francis Ltd. United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Expert Review of Hematology is a journal indexed in SJR in Hematology with an H index of 58. It has a price of 4000 €. It has an SJR impact factor of 0,724 and it has a best quartile of Q2. It has an SJR impact factor of 0,724.

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Hematology (Q2)

Price

4000 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

0,724

SJR Impact factor

58

H Index

97

Total Docs (Last Year)

326

Total Docs (3 years)

6940

Total Refs

724

Total Cites (3 years)

299

Citable Docs (3 years)

2.02

Cites/Doc (2 years)

71.55

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Thrombosis Research Q2
Cancer Control Q2
Annals of Hematology Q2
Platelets Q2
Transfusion Medicine Reviews Q2

Compare this journals

Aims and Scope

Best articles by citations

Therapy-free remission in chronic myeloid leukemia: possible mechanism

Role of microRNAs in hematological malignancies

Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options

Management of asymptomatic myeloma patients

Targeted molecular therapy in peripheral T-cell lymphomas

Chimeric antigen receptor T cells: power tools to wipe out leukemia and lymphoma

Synovium and cartilage biomarkers in hemophilic arthropathy

Highlights in lymphoma: overview of the 11th International Conference on Malignant Lymphoma

ESH-SIOG International Conference on Haematological Malignancies in the Elderly

Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance

Highlights in the treatment of chronic lymphocytic leukemia from the 2014 meeting of the American Society of Hematology

The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery

SHOW MORE ARTICLES

A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment

SALL4: finally an answer to the problem of expansion of hematopoietic stem cells?

Hairy cell leukemia: current therapies and future directions

When to treat patients with relapsed follicular lymphoma

Therapeutic targeting of Bcl-2 family for treatment of B-cell malignancies

Hemophilia care in China: review of care for 417 hemophilia patients from 11 treatment centers in Shanxi Province

Stroke in patients with sickle cell disease

Management of bone disease in multiple myeloma

Refeeding syndrome in hematological cancer patients -current approach

Point mutations which should not be overlooked in Hb H disease

Fondaparinux: does it cause HIT? can it treat HIT?

Managing cancer-related venous thromboembolic disease: low-molecular-weight heparins and beyond